LONDON, October 31, 2014 /PRNewswire/ --
Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 30, 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced 1.30%, to finish the day at 17,195.42, and the S&P 500 closed at 1,994.65, up 0.62%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index also advancing 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
Nanosphere Inc.'s stock edged 0.27% higher, to close the day at $0.44. The stock recorded a trading volume of 5.36 million shares, much above its three months average volume of 1.65 million shares. The stock oscillated between $0.43 and $0.50 during the session. Over the last three trading sessions and over the past one month, Nanosphere Inc.'s shares have declined 10.00% and 22.63%, respectively. Further, the stock has plummeted 80.74% since the start of this year. The company's stock closed below its 50-day and 200-day moving averages. The stock's 200-day moving average of $1.51 is above its 50-day moving average of $0.66. Additionally, Nanosphere Inc. has a Relative Strength Index (RSI) of 39.90. Sign up and read the free notes on NSPH at:
On Thursday, shares in Isis Pharmaceuticals Inc. recorded a trading volume of 2.08 million shares, which was at par with its three months average volume. The stock ended the day at $45.88, which was 1.93% above its previous day's closing of $45.01, and registered an intraday range of $44.56 and $46.40. Isis Pharmaceuticals Inc.'s shares have surged 18.16% in the last one month, 43.91% in the previous three months and 15.16% on YTD basis. The company's stock closed above its 50-day and 200-day moving averages of $39.73 and $38.32, respectively. Furthermore, shares of Isis Pharmaceuticals Inc. have an RSI of 63.98. The complimentary notes on ISIS can be downloaded as in PDF format at:
Halozyme Therapeutics Inc.'s stock gained 3.22%, to close Thursday's session at $9.61, after oscillating between $9.17 and $9.65. The stock recorded a trading volume of 1.14 million shares, below its three months average volume of 1.31 million shares. Halozyme Therapeutics Inc.'s shares have advanced 5.60% in the last one month and 4.12% in the previous three months. However, from the beginning of 2014, the stock has lost 35.89%. The company's stock closed above its 50-day moving average of $9.29, while the 50-day moving average is below Halozyme Therapeutics Inc.'s 200-day moving average of $10.49. Further, the stock has an RSI of 53.41. Register for free on Investor-Edge and access the latest research on HALO at:
ACADIA Pharmaceuticals Inc.'s stock finished Thursday's session 1.52% higher at $28.05. A total of 1.28 million shares were traded, which was above its three months average volume of 1.19 million shares. The stock moved between $27.42 and $28.64 during the session. Over the last one month and the previous three months, ACADIA Pharmaceuticals Inc.'s shares have surged 13.29% and 32.25%, respectively. Additionally, from the beginning of 2014, the stock has gained an upside of 12.24%. The company's shares closed above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $25.61 is greater than its 200-day moving average of $23.36. ACADIA Pharmaceuticals Inc.'s stock has an RSI of 61.59. The complete research on ACAD is available for free at:
On Thursday, shares in Synta Pharmaceuticals Corp. traded between $2.88 and $3.12 before ending the session 1.69% higher at $3.01. The stock reported a trading volume of 1.09 million shares, below its three months average volume of 1.37 million shares. Although, Synta Pharmaceuticals Corp.'s shares have advanced 2.38% in the previous three trading sessions, it has declined 24.94% in the last three months and 42.56% on YTD basis. The company's stock below its 50-day and 200-day moving averages of $3.44 and $4.35, respectively. Moreover, shares of Synta Pharmaceuticals Corp. have an RSI of 42.26. Free in depth research on SNTA is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.